FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 353:2086-2087 November 10, 2005 Number 19 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Keymeulen, B. PubMed Citation

To the Editor: We urge caution regarding the conclusion of Keymeulen et al. (June 23 issue)¹ in reporting their study of CD3-antibody therapy for new-onset type 1 diabetes mellitus that treatment with ChAglyCD3 preserves residual beta-cell function. Differences in C-peptide levels between the study groups at six months suggest a benefit of treatment. However, increases in C-peptide levels in treated patients at 6 months, with decreases in C-peptide levels in controls, appear to account for most of the improvement in the treated group at 18 months. After six months, the rate of C-peptide loss is almost identical in both groups. . . . [Full Text of this Article]

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.